Recent Updates
Recently added Catalysts
ATHE Positive Sentiment Score: 70/100

Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen

Monday, January 6, 2025 4 min read
Key Takeaway: Alterity Therapeutics Limited has reported significant changes in the ownership interests of its directors, as per the ASX guidelines. Mr. Brian Meltzer acquired 30 million options, raising his total options to approximately 39 million. Similarly, Mr. Lawrence Gozlan's holdings increased to 57 million options following the acquisition of 50 million options under the company's Employee Stock Ownership Plan. These changes indicate a strong commitment from the directors towards the company's future.

Market Sentiment Analysis

POSITIVE FACTORS

  • Notable acquisition of 30 million options by Mr. Brian Meltzer.
  • Increase in director's options holdings to nearly 39.4 million.
  • Significant issuance of 50 million options under the ESOP for director Mr. Lawrence Gozlan.

Full Press Release Details

Change of Director's Interest
of Director's Interest Notice
Information or documents not available now must be given
to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.. Amended
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ABN: 37 080 699 065
We (the entity) give ASX the following information under
listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Mr. Brian Meltzer
Date of Last Notice: 20 September 2024
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in
the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. -
Date of change 30 December 2024
No. of securities held prior to change Shares Options
Direct 7,142,857 9,380,952
Indirect 326,666 -
Total 7,469,523 9,380,952
Class Unlisted Options
Number acquired
Shares Options
Direct - 30,000,000
Indirect - -
Total - 30,000,000
Number disposed
Shares Options
Direct - -
Indirect - -
Total - -
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Y Page 1
Change of Director's Interest Notice
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation n/a
No. of securities held after change
Shares Options
Direct 7,142,857 39,380,952
Indirect 326,666 -
Total 7,469,523 39,380,952
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Incentive options under ESOP
Part 2 - Change of director's interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Change of Director's Interest Notice
Change of Director's Interest
Information or documents not available now must be given
to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001. Amended
Name of Entity: Alterity Thesrapeutics Limited (ASX:ATH)
ABN: 37 080 699 065
We (the entity) give ASX the following information under
listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Mr. Peter Marks
Date of Last Notice: 20 September 2024
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in
the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. -
Date of change 30 December 2024
No. of securities held prior to change
Shares Options
Direct - 7,000,000
Indirect 7,185,968 2,380,952
Total 7,185,968 9,380,952
Class Unlisted Options
Number acquired
Shares Options
Direct - 30,000,000
Indirect - -
Total - 30,000,000
Number disposed
Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation n/a
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director's Interest Notice
No. of securities held after change
Shares Options
Direct - 37,000,000
Indirect 7,185,968 2,380,952
Total 7,185,968 39,380,952
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Incentive options under ESOP
Part 2 - Change of director's interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Change of Director's Interest Notice
of Director's Interest Notice
Information or documents not available now must be given
to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001. Amended
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ABM: 37 080 699 065
We (the entity) give ASX the following information under
listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Mr. Lawrence Gozlan
Date of Last Notice: 15 December 2022
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in
the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. -
Date of change 30 December 2024
No. of securities held prior to change
Shares Options
Direct - 7,000,000
Indirect - -
Total - 7,000,000
Class Unlisted Options
Number acquired
Shares Options
Direct - 50,000,000
Indirect - -
Total - 50,000,000
Number disposed
Shares Options
Direct - -
Indirect - -
Total - -
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director's Interest Notice
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation n/a
No. of securities held after change
Shares Options
Direct - 57,000,000
Indirect - -
Total - 57,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Incentive options under ESOP
Part 2 - Change of director's interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Change of Director's Interest Notice
Change of Director's
Information or documents not available now must be given
to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.. Amended
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ABN: 37 080 699 065
We (the entity) give ASX the following information under
listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Mr. Geoffrey Kempler
Date of Last Notice: 15 December 2022
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in
the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Director related entity
Date of change 30 December 2024
No. of securities held prior to change
Shares Options
Direct 30,000 14,000,000
Indirect 17,981,000 -
Total 18,011,000 14,000,000
Class Unlisted Options
Number acquired
Shares Options
Direct - 60,000,000
Indirect - -
Total - -
Number disposed
Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation n/a
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Y Page 1
Change of Director's Interest Notice
No. of securities held after change
Shares Options
Direct 30,000 74,000,000
Indirect 17,981,000 -
Total 18,011,000 74,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Incentive options under ESOP
Part 2 - Change of director's interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011

Frequently Asked Questions

What is the date of change for Brian Meltzer's interests?

The date of change for Brian Meltzer's interests is 30 December 2024.

How many shares does Mr. Lawrence Gozlan hold after the change?

After the change, Mr. Lawrence Gozlan holds 57,000,000 shares.

What type of options were acquired by Peter Marks?

Peter Marks acquired unlisted options under an employee stock ownership plan (ESOP).

Is prior written clearance needed for closed period trades?

No, prior written clearance was not needed for trading during a closed period.

How many total securities does Mr. Meltzer have after the change?

Mr. Meltzer has a total of 46,860,475 securities after the change.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics director's interest options acquisition corporate governance
Last updated: Jan 6, 2025